New hope for HIV patients with kaposi sarcoma: study tests cheaper chemo options
NCT ID NCT05411237
First seen Dec 12, 2025 · Last updated Apr 30, 2026 · Updated 20 times
Summary
This study compares two chemotherapy drugs, paclitaxel and pegylated liposomal doxorubicin, to see if they work equally well for treating Kaposi sarcoma in people with HIV. The trial will enroll 130 participants in sub-Saharan Africa, where resources are limited. Each person will receive one of the drugs every 3 weeks for 6 cycles, and researchers will track how long the cancer stays under control and what side effects occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.